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Abstract The EDA? fibronectin splicing variant is over-
expressed in psoriatic non-lesional epidermis and sensitizes
keratinocytes to mitogenic signals. However, regulation of
its abundance is only partially understood. In our recent
cDNA microarray experiment, we identified three SR-rich
splicing factors—splicing factor, arginine/serine-rich 18
(SFRS18), peptidyl-prolyl cis–trans isomerase G (PPIG),
and luc-7 like protein 3 (LUC7L3)—which might be
implicated in the preactivated states of keratinocytes in
psoriatic non-involved skin and could also contribute to the
regulation of fibronectin mRNA maturation. In this study,
we investigated the role of LUC7L3, PPIG, and SFRS18 in
psoriasis and in the mRNA maturation process of fibro-
nectin. Regarding tissue staining experiments, we were
able to demonstrate a characteristic distribution of the
splicing factors in healthy, psoriatic non-involved and
involved epidermis. Moreover, the expression profiles of
these SR-rich proteins were found to be very similar in
synchronized keratinocytes. Contribution of splicing
facwwtors to the EDA? fibronectin formation was also
confirmed: their siRNA silencing leads to altered fibro-
nectin mRNA and protein expression patterns, suggesting
the participation in the EDA domain inclusion. Our results
indicate that LUC7L3, PPIG, and SFRS18 are not only
implicated in EDA? fibronectin formation, but also that
they could possess multiple roles in psoriasis-associated
molecular abnormalities.
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Introduction
During the past few years, huge advances have been made
in the field of psoriasis research; however, the exact
molecular background of this chronic inflammatory disor-
der has not been fully revealed and many questions remain
to be answered. Development of psoriatic lesions is asso-
ciated with keratinocyte hyperproliferation and abnormal
T-lymphocyte function, although it is still controversial
whether epithelial or immunological elements are deter-
minant in the primary phase of the disease. The extent to
which genetic and environmental factors lead to the dis-
order is also a subject of discussion [1–3].
Recently, a novel molecular factor has been identified
that might be responsible for the elevated responsiveness of
keratinocytes to the stimuli of professional immune cells.
This putative factor is a splice variant of fibronectin that
contains the oncofetal EDA domain (EDA? fibronectin)
[4–6]. Although fibronectin is an excellent model for
studying splicing (having more than 20 mRNA variants),
processes regulating mRNA maturation and the mecha-
nisms affecting EDA? fibronectin formation are not fully
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understood [7, 8]. The EDA domain is a Type III repetitive
module of fibronectin, typically present during embryonic
development. Although the tendency is exclusion of the
EDA domain in the adult organism, EDA? fibronectin is
elevated under some circumstances, including wound
healing, inflammation, and malignant processes [8–13]. In
psoriasis, elevated EDA? fibronectin expression was
described for psoriatic non-involved epidermis, and we
showed that proliferating keratinocytes are able to produce
this isoform [4, 5].
Several molecular factors in addition to EDA? fi-
bronectin have been implicated in psoriasis pathogenesis.
Application of large-scale gene expression studies extended
our knowledge regarding molecular abnormalities in
involved and non-involved epidermis [14–19]. Recent RNA-
Sequencing-based experiments have indicated that a large
number of mRNAs are consistently differentially expressed
in healthy and involved skin samples across independent
studies, at both the transcript and gene levels [20, 21].
Specifically, a systematic comparison of the above-men-
tioned datasets indicated over 10,000 differentially expres-
sed transcripts, suggesting the potential role of mRNA
maturation processes in psoriasis development [22].
In a recently performed cDNA microarray experiment,
we aimed to compare the responsiveness of healthy and
psoriatic non-involved epidermis to treatment with a mix-
ture of T-lymphokines (GM-CSF, IFN-c, IL-3) previously
shown to induce psoriatic plaque formation [23, 24].
Functional characterization of the identified genes
exhibiting differential regulation upon T-lymphokine
treatment showed that they play a role in several cellular
procedures including the influence of cell morphology,
development, and cell death. Moreover, a set of these genes
participate in the metabolism of small lipids [23]. Among
these genes were three that are implicated in mRNA mat-
uration: splicing factor, arginine/serine-rich 18 (SFRS18,
also known as PNN-interacting serine/arginine-rich pro-
tein, PNISR), peptidyl-prolyl cis–trans isomerase G
(PPIG), and luc-7 like protein 3 (LUC7L3). Products of
these genes belong to the family of SR-rich proteins and
function as trans-regulators of splicing events (UniProtKB-
O95232 (LC7L3_HUMAN); UniProtKB-Q13427
(PPIG_HUMAN); UniProtKB-Q8TF01 (PNISR_HU-
MAN)). This finding is notable, as relatively few articles
mention the relationship between psoriasis and distur-
bances of mRNA maturation.
In our study, characteristics of splicing-factor expression
were examined in synchronized, immortalized cell cultures
and skin samples. Since the regulation of fibronectin splicing
is only partially elucidated, we aimed to determine whether
these newly identified splicing factors participate in the pro-
ductionof theEDA? fibronectin isoform.For this purpose, an
in vitro functional assay was constructed to detect changes in
fibronectin splicing patterns during decreased expression of
the LUC7L3, PPIG, and SFRS18 splicing factors.
Materials and methods
Skin biopsies
To carry out our cDNA microarray experiment, 4 healthy
volunteers and 4 patients (age 18–60 years) with moderate-
to-severe chronic plaque-type psoriasis (Psoriasis Area and
Severity Index score determined by dermatologists) were
enrolled in the study after a medication-free period
of C4 weeks without systemic therapy and/or C2 weeks
without local therapy. Prior to surgical intervention, par-
ticipant-informed consent was obtained. Tissue collection
complied with the guidelines of the Declaration of Helsinki
and was approved by the Regional and Institutional
Research Ethics Committee (2799, 3517).
Organotypic skin cultures
Organotypic skin cultures were established from each half-
cut from shave biopsies [23]. Briefly, epidermis samples
placed on cellulose acetate/cellulose nitrate filters (2.2 lm
porosity, Millipore) were transferred to a stainless steel
grid platform in a 6-well plate. As culture medium, Dul-
becco’s modified Eagle’s medium (DMEM) supplemented
with 12 mM glutamine, 100 units/ml penicillin, and
100 lg/ml streptomycin (all from Life Technologies,
Carlsbad, CA) was applied. For all donor skin specimens,
one-half of the organotypic cultures was treated with the
lymphokine mixture, containing 1 ng/ml IFNc, 1 ng/ml
GM-CSF, and 0.3 ng/ml IL-3, and the other half was not
treated. Using standard culturing conditions (at 37 C in a
5% CO2 atmosphere), organotypic skin cultures were
maintained at the air/liquid interface for 72 h. Subse-
quently, the epidermis was separated from the dermis by
overnight incubation in Dispase solution (grade II, Roche
Applied Science) at 4 C, and then placed in TRI Reagent
(Molecular Research Center Inc., Cincinnati, OH).
Real-time RT-PCR
One microgram of total RNA purified from organotypic
skin culture samples, HPV-KER and HaCaT cells were
reverse transcribed using the iScript TM cDNA Synthesis
kit (#1708891, Bio-Rad, Hercules, CA). RT-PCR was
performed with the cDNA to quantify transcript abundance
using custom primer sets and the Universal Probe Library
(Roche, Basel, Switzerland) with an iQ Supermix
(#1708862, Bio-Rad, Hercules, CA). Relative gene
expression data were calculated by normalizing the
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expression data for the 18S ribosomal RNA and using the
DDCt method.
Immunofluorescent staining
Biopsies were frozen, embedded, stored at -80 C, and
then cut into 6-lm sections. The following primary anti-
bodies were used: LUC7L3 (1:300, Abcam, Cambridge,
UK), PPIG (1:300, Abcam), and SFRS18 (1:250, Novus
Biologicals, Littleton, USA). Anti-mouse IgG-Alexa Fluor
647 and anti-rabbit Alexa Fluor 546 were used as sec-
ondary antibodies, both at 1:500 dilution (Life Technolo-
gies, Carlsbad, CA). For negative staining controls,
sections were incubated without the primary antibody (in
case of PPIG) or with normal rabbit IgG as isotype control
antibody (Santa Cruz Biotechnology, Dallas, TX, USA).
Nuclei were stained with 2-(4-amidinophenyl)-1H-indole-
6-carboxamidine (DAPI).
Fluorescent microscopic images were analyzed using
ImageJ software, by calculating corrected-total-cell-fluo-
rescence values based on integrated density of stained cell
areas.
Culturing of HPV-KER and HaCaT cells
The HPV-KER cell line was immortalized by the HPV E6
oncogene as described by our research group [25]. HPV-
KER cells were grown in 75 cm2 cell culture flasks and
maintained in keratinocyte serum-free medium (Gibco
Keratinocyte SFM Kit; Life Technologies, Copenhagen,
Denmark) supplemented with 1% antibiotic/antimycotic
solution (PAA, Pasching, Austria) and 1% L-glutamine
(PAA) at 37 C in a humidified atmosphere containing 5%
CO2. The medium was changed every two days.
During synchronization of the HPV-KER cells and after
confluence was obtained, cells were maintained in glu-
tamine-free and growth factor-free keratinocyte SFM for one
week. Cells were harvested with brief trypsinization (0.25%
trypsin solution Sigma Aldrich, St. Louis, MO, USA)
Immortalized HaCaT keratinocytes were kindly pro-
vided by Dr. Fusenig, N.E. (Heidelberg, Germany). Cells
were synchronized as described previously [26].
Western blot analysis
For western blot analysis, equal amounts of proteins were
separated on a 10% SDS-PAGE gel and transferred to Pure
Nitrocellulose Membrane (Bio-Rad Laboratories). Primary
antibodies were the following: LUC7L3 (1:300, Abcam,
Cambridge, UK), PPIG (1:300, Abcam), and SFRS18
(1:300, Novus Biologicals, Littleton, US). Anti-mouse and
anti-rabbit IgG alkaline phosphate conjugate (Sigma
Aldrich, St. Louis, MO, USA) was used as a secondary
antibody, and signals were visualized with Sigma Fast TM
BCIP/NBT (Sigma Aldrich, St. Louis, MO, USA). An a-
actin-specific antibody was used as a loading control
(1:2000, Sigma Aldrich, St. Louis, MO, USA).
Gene-specific silencing
Gene-specific silencing was performed with an siRNA
transfection method. HPV-KER cells were transiently
transfected at approximately 70% confluency. siRNA
silencing (transfection reagent and medium) was ordered
from Santa Cruz Biotechnology (Dallas, TX, USA). In
silencing experiments, scrambled and gene-specific
LUC7L3, PPIG, SFRS18 siRNA duplexes were applied. The
most effective silencing was achieved in serum-free culture
medium without additive and supplements. The effective-
ness of silencing was confirmed by real-time RT-PCR.
Polymerase chain reaction
Samples were collected from the cultures of silenced HPV-
KER cells. Total RNA was isolated from cell cultures by
TRIzol Reagent (Invitrogen Corp., Carlsbad, CA, USA),
following the instructions provided in the manual. cDNA
was synthesized from 1 lg total RNA with the iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA,
USA). Primers specific for human fibronectin (50-AAGC-
CAATTTCCATTAATTACCGAAC-30 and 50-TCTCA-
TACT TGATGATGTAGCCGGTAA-30) were used to
amplify a 1221 bp product from the EDA? template and
an 847 bp product from the EDA- fibronectin template.
PCR conditions are described in Szell et al., and detection
and semiquantitative analysis of the differentially spliced
fibronectin form are also demonstrated in this paper [4].
Ten microliters of the PCR products were run on 1%
agarose gel, photographed and evaluated using Bio-Rad
Gel Doc XR densitometer.
Flow cytometry
Cells were collected after a brief trypsinization (0.25%
trypsin solution Sigma Aldrich, St. Louis, MO, USA), fixed
in Fixation/Permeabilization Concentrate and Diluent
(eBioscience, San Diego, USA), and resuspended in PBS.
Primary antibodies (anti-EDA?-fibronectin, anti-fi-
bronectin, 1:500 and 1:1000, respectively, Sigma Aldrich,
St. Louis, MO, USA) were applied for 45 min. Cells were
then washed in PBS and incubated with anti-mouse IgG-
Alexa Fluor 647 (Life Technologies, Carlsbad, CA) as
secondary antibody, at 1:500 dilution. Samples were ana-
lyzed on a FACSCalibur flow cytometer equipped with 488
and 633 nm lasers (Becton–Dickinson, Franklin Lakes, NJ,
USA).
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Statistical analysis and bioinformatics
Statistical analysis was performed in GraphPad Prism 5.0
Software (GraphPad Prism, San Diego, CA), using one-
sample t- and unpaired t-tests with a p\ 0.05 significance
threshold.
Predictive interaction analysis was carried out using the
publicly available STRING database (http://string-db.org/).
Results
Differential expression of splicing-factor genes
confirmed for psoriasis
LUC7L3, PPIG, and SFRS18 splicing regulators have been
identified in our above-mentioned cDNA microarray
experiment. An overview of our approach is presented in
Fig. 1.a. Briefly, gene expression before and after lym-
phokine treatment was compared in healthy epidermis, and
we applied the same approach to non-involved psoriatic
skin. Genes exhibiting at least a two-fold change in relative
expression have been chosen for further comparison. We
then selected the genes showing significant differences in
mean expression between the control and psoriatic non-
involved samples [23]. Real-time reverse-transcription
polymerase chain reaction (RT-PCR) was carried out to
verify whether the identified genes are differentially regu-
lated in psoriasis. The T-lymphokine induced alterations
were confirmed in the case of both LUC7L3 and PPIG
splicing factors (Fig. 1b) Although we were not able to
validate the cDNA microarray results for SFRS18 in the
RT-PCR experiment, we decided to include this gene in
further experiments as it participates in similar biological
processes as LUC7L3 and PPIG.
Expression of the splicing factors was also compared in
untreated healthy and psoriatic non-involved epidermis
samples of the microarray experiment: in this setup, the
expression of LUC7L3 and SFRS18 was slightly higher in
psoriatic non-involved epidermis than in healthy samples
(Fig. 1c).
Differentially expressed splicing factors
in psoriasis
As the splicing factors showing altered mRNA expression
in psoriasis are poorly characterized, we examined the
pattern of protein expression in healthy, psoriatic non-in-
volved and involved skin samples. LUC7L3 and PPIG
exhibited nuclear localization, whereas SFRS18 showed
perinuclear staining (Fig. 2a). LUC7L3 is present in sig-
nificantly higher amounts in psoriatic non-involved
epidermis, whereas SFRS18 shows only minimal, non-
significant elevation in non-involved epidermis. The
highest levels of expression of LUC7L3 and SFRS18 were
found in psoriatic involved epidermis samples. The
expression pattern of PPIG was different from that of the
other splicing factors: PPIG amounts were significantly
lower in psoriatic non-involved epidermis than in healthy
and psoriatic samples; however—similarly to LUC7L3 and
SFRS18—the highest expression was also detected in
psoriatic involved epidermis (Fig. 2b).
LUC7L3, PPIG, and SFRS18 expression patterns
in synchronized cells
To compare the expression levels in proliferating and dif-
ferentiating keratinocytes, both mRNA and protein
expression patterns of the selected splicing factors were
analyzed in synchronized, immortalized cells. HPV-KER
cells were synchronized by contact inhibition and in the
absence of growth factors [22]. Cells were harvested at
various time points after release from cell quiescence, and
RNA and protein levels were measured by real-time RT-
PCR and western blot analysis, respectively.
Comparing the expression of the splicing factors during
the proliferation and differentiation phases, a very similar
mRNA expression pattern was observed for all three
splicing factors (Fig. 3a). mRNA expression decreased at
12 h. The first peak of mRNA abundance was seen at 24 h,
with steady elevation starting from 48 h, a phenomenon
that is likely induced by cellular stress processes. This
synchronization experiment was repeated using synchro-
nized, immortalized HaCaT cells: the splicing regulators
exhibited an identical pattern of gene expression in HaCaT
cells that were observed in the HPV-keratinocytes (Suppl.
Fig. 1).
The pattern of expression in HPV-KER cells of both
RNA and protein was similar. However, protein expression
was more even across sampled time points than for mRNA.
The highest expression of LUC7L3, PPIG, and SFRS18
protein was detected at 48 h after release from cell quies-
cence (Fig. 3b).
cFig. 1 Experimental design and comparisons used in our previous
cDNA microarray study is summarized in (a). Gene expression
changes of LUC7L3, PPIG, and SFRS18 splicing factors induced by
T-lymphokine treatment were compared in healthy (H, n = 4) and
psoriatic non-involved (PS, n = 4) epidermis samples (b), where the
average expression level of untreated samples was considered as
baseline expression (relative unit of 1 indicated by dashed line).
Comparison of LUC7L3, PPIG, and SFRS18 basal mRNA expression
levels in untreated healthy (H, n = 4) and psoriatic non-involved (PS,
n = 4) epidermis. p\ 0.05 was considered significant (c)
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Fig. 2 Immunofluorescent staining of PPIG, LUC7L3, and SFRS18
proteins (a) was carried out on healthy (n = 3), psoriatic non-
involved (n = 3), and psoriatic involved (n = 3) samples. One
representative staining is provided for each protein. Magnification:
940. Fluorescent intensity measurements of PPIG, LUC7L3, and
SFRS18 (b) in non-involved and involved epidermis compared to
healthy samples are indicated as follows: dashed lines represent the
unaltered condition, where the ratio of non-involved/healthy and
involved/healthy is 1; significance levels are indicated by asterisks
(*p\ 0.05, **p\ 0.01, ***p\ 0.001)
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Silencing of PPIG, SFRS18, and LUC7L3 affects
fibronectin splicing
To determine the physiological relevance of LUC7L3,
PPIG, and SFRS18 in the fibronectin mRNA maturation
processes, HPV-KER cells were transfected with siRNA
constructs silencing these splicing-factor genes. The
EDA?/total fibronectin ratios were compared in scrambled
and gene-specific siRNA-transfected cells, and the mean of
silencing efficacies was approximately 80% (summarized
in Suppl. Fig. 2). Changes in the fibronectin splicing pat-
tern were investigated by RT-PCR, and densitometry
analysis was applied as an accurate and semiquantitative
method to determine changes in the EDA?/total ratio in
response to silencing of the three different splicing factors
either alone or in combination.
In the experiments where a single splicing factor was
silenced, siRNA transfection of LUC7L3 has lowered the
EDA?/total ratio for fibronectin, and a slight decrease in
this ratio was also seen with PPIG and SFRS18 silencing
(Fig. 4a). In the scrambled RNA-transfected samples, the
relative amount of the EDA? variant was higher compared
to the EDA- fibronectin isoform.
Bioinformatics analysis suggests that LUC7L3 and
SFRS18 are interacting partners (Fig. 4c). Therefore,
experiments in which two or three genes were silenced
were also performed to examine the possible interactions
among the splicing factors. The combined silencing of
Fig. 3 HPV-KER cells were synchronized by contact inhibition and
by withdrawal of supplement, and samples were taken at the indicated
time points from the re-passaged (0 h) cells. Changes in mRNA levels
(a) were followed by real-time RT-PCR and changes in protein levels
(b) were followed by western blot analysis. The experiment was
carried out with three independent series of cell cultures. The mRNA
expression data were calculated as the average of these three parallel
experiments. One representative western blot is provided for each
splicing factor. a-actin was used as a loading control
Mol Cell Biochem (2017) 436:189–199 195
123
196 Mol Cell Biochem (2017) 436:189–199
123
LUC7L3 and SFRS18 leads to the most robust change in
the EDA?/total ratio of fibronectin (Fig. 4a). Notably,
silencing of all three splicing factors had no additional
effect on the ratio compared to the double silencing of
LUC7L3 and SFRS18.
The effect of silencing was also examined at the protein
level. Total and EDA? fibronectin amount was measured
with flow cytometry using the most effective combination
of double LUC7L3 and SFRS18 silencing. Similar to the
mRNA experiments, the immortalized HPV-keratinocytes
expressed high levels of EDA? fibronectin protein. This
double silencing significantly diminished the quantity of
EDA? fibronectin, without decreasing the total amount of
fibronectin (Fig. 4b). Taken together, these results
demonstrate that silencing of the splicing factors decreased
the EDA?/total fibronectin ratio both at mRNA and pro-
tein level.
Discussion
The importance of fibronectin as an excellent model for
studying splicing events as well as the importance of var-
ious fibronectin isoforms—including variants containing
the EDA and EDB domains—is increasingly being
acknowledged. It was previously shown that EDA? fi-
bronectin is overexpressed in samples of psoriatic non-in-
volved epidermis [5]. Some years later, our research group
reported that both normal cultured keratinocytes and
HaCaT cells produce the oncofetal EDA? fibronectin
isoform. Moreover, it has also been proven that ker-
atinocytes from psoriatic non-involved epidermis are
sources of EDA? fibronectin, while the expression of this
isoform is minimal in healthy keratinocytes. These data
suggest that EDA? fibronectin might initiate a signal
transduction process that sensitizes keratinocytes to the
mitogenic signals of immune cells [4].
In our recently performed cDNA microarray experi-
ment, we aimed to reveal that novel molecular factors
make it prone to form psoriatic lesions. From this work, we
identified three splicing factors that participate in the
molecular processes of mRNA maturation. In addition to
regulation of splicing, PPIG is responsible for the normal
folding of proteins, and LUC7L3 has been implicated in
cisplatin resistance in tumor cells [27–29]. PPIG and
SFRS18 are physical interactors of the splicing factor and
the desmosome-associated protein, pinin [27, 30].
Our study opens the questions whether LUC7L3, PPIG,
and SFRS18 are involved in the mRNA maturation process
of fibronectin and whether the altered expression of these
splicing factors can be linked to the documented presence
of EDA? fibronectin in psoriasis. Although EDA? fi-
bronectin is known to be involved in several biological
processes, the regulation of its synthesis is not completely
understood. TGF-b is known to promote inclusion of EDA
domain [31–33]. Other research groups reported that the
SR-rich protein SF2/ASF exerts a similar effect, whereas
heterogeneous ribonucleoprotein particles inhibit its
inclusion [8, 34, 35]. According to the latest findings,
keratinocyte growth factor (KGF) slightly increases the
formation of the EDA? variant, and STAT1 induces
exclusion in fibroblasts [36].
Based on our results, LUC7L3 might have a direct
regulatory role on EDA? domain inclusion: similarly to
the EDA? fibronectin, its protein level is also increased in
non-involved epidermis. SFRS18 showed only a minimal
tendency towards elevation. PPIG amounts are decreased
in non-involved epidermis compared to healthy controls,
and this expression pattern resembles that which we pre-
viously observed for STAT1, another component of the
EDA? fibronectin-related molecular pathway. Moreover,
similar to STAT1, PPIG proved to be part of the functional
molecular network involving KGF and fibronectin signal-
ing [36].
Another relevant outcome of our current study is that all
three splicing factors exhibit the highest level of staining in
psoriatic involved epidermis, with approximately 2- to
3-fold elevation in involved epidermis compared to non-
involved samples. These data indicate that the examined
splicing factors could influence the mRNA maturation of
several other molecular components involved in the
inflammatory and proliferative processes of psoriatic
lesions.
In addition to tissue staining, results from in vitro
characterization of splicing regulator expression also sup-
port the congruent pattern detected in psoriatic involved
bFig. 4 HPV-KER cells were transfected with specific silencing
constructs for LUC7L3, PPIG, and SFRS18 (a) and the ratio of
EDA? fibronectin mRNA was calculated in each repeated experi-
ment (S1, S2, S3). The changes in this ratio were compared to that of
the scrambled RNA-transfected controls (C1, C2, C3) in each
experiment. Comparison of the effect of double and triple silencing
of the LUC7L3, PPIG, and SFRS18 genes to the scrambled RNA-
transfected controls revealed that the double silencing of LUC7L3 and
SFRS18 resulted in the most robust changes in the EDA?/total ratio
of fibronectin mRNA. Effect of triple silencing did not differ
significantly from that of LUC7L3 and SFRS18 double silencing.
Columns represent means of three independent experiments (?SE),
all performed in triplicate. Significance levels are indicated by
asterisks ( *p\ 0.05, **p\ 0.01, ***p\ 0.001). Total fibronectin
and EDA? fibronectin were detected by flow cytometry in HPV-KER
cells (n = 5) in which both LUC7L3 and SFRS18 were silenced (b).
Silencing did not affect the amount of total fibronectin, whereas a
significant (p\ 0.05) decrease in the amount of the EDA? fi-
bronectin was detected after silencing, and this decrease resulted in
significant (p\ 0.01) changes in the EDA?/total ratio of fibronectin.
Bioinformatics analysis revealed a predicted functional interaction
between the LUC7L3 and SFRS18 splicing regulators (c)
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epidermis. In synchronized, immortalized keratinocytes,
remarkable similarities in the expression patterns were
observed both at the RNA and protein levels. Genetic
linkage does not account for these similarities, as the
LUC7L3, SFRS18, and PPIG genes are located on different
chromosomes. Instead, the corresponding mRNAs might
possess common transcription-factor binding sites and
upstream regulators. Based on western blot analysis and
immunofluorescent staining results, we conclude that
expression of the three splicing factors is marked in both
immortalized keratinocytes and involved epidermis. This
finding supports that elevated amounts of LUC7L3, PPIG,
and SFRS18 might be responsible for the shortened and
abnormal maturation of keratinocytes that is a character-
istic of psoriatic epidermis and is also typical of the
immortalized HPV-KER cells.
The influence of the LUC7L3 splicing regulator on the
formation of EDA? fibronectin was also confirmed by
in vitro experiments. We demonstrated that immortalized
HPV-KER cells express the oncofetal EDA? isoform of
fibronectin in higher amounts than the EDA- isoform.
LUC7L3 silencing resulted in the decrease of the
EDA?/total ratio for fibronectin, indicating that the rela-
tive amount of EDA- fibronectin is elevated in response to
LUC7L3 silencing. Similar results were obtained with
silencing of PPIG and SFRS18, although the changes in the
EDA?/total fibronectin ratios were more moderate than
with LUC7L3 silencing. These data suggest that the three
splicing factors promote exon inclusion of the EDA
domain. This finding is in accordance with previous work
showing that another type of SR protein, SF2/ASF, sup-
ports the inclusion of the EDA element [34, 35].
Double silencing of SFRS18 and LUC7L3 was the most
effective in decreasing the EDA?/total ratio of fibronectin,
as expected from the results of bioinformatics analysis.
Moreover, LUC7L3 and SFRS18 exhibited a similar pattern
of expression during immunofluorescent staining. To ana-
lyze whether the changes in the EDA?/total fibronectin ratio
detected by PCR are similar at the protein level, flow cyto-
metric measurements were performed in cells in which both
SFRS18 and LUC7L3 were silenced. The EDA?/total ratio
for fibronectin protein decreased in these experiments. The
quantity of total fibronectin was constant before and after
silencing, and the ratio changes were thus due to increased
production of the EDA- fibronectin isoform via an altered
splicing mechanism. In addition to SF2/ASF, other SR-rich
proteins have also been shown to promote inclusion of the
EDA domain. This finding is of special interest, considering
that SR proteins usually interact with enhancer splicing
elements, inducing exon inclusion [37–39].
Several previous studies indicate that alternative splic-
ing changes the binding characteristics of fibronectin rad-
ically [6, 8, 13, 40]. The a5b1 integrin receptor is one of
the most important interacting partners for fibronectin, and
the inclusion of the EDA domain has been shown to
increase affinity towards this receptor [6, 40, 41]. However,
a contradicting report demonstrated that the EDA domain
does not bind to a5b1 integrin [8]. It is also well docu-
mented that EDA? fibronectin binds to the TLR4 receptor,
which is part of the innate immune system [6, 33, 42]. It
would be a very interesting new approach to study the
changes of TLR4-mediated signal transduction in response
to the altered expression of splicing factors.
Taken together, LUC7L3 might—through inclusion of the
EDA domain and, thus, elevation of EDA? fibronectin
abundance in the epidermis—contribute to an autocrine loop
by which psoriatic keratinocytes maintain hyper-responsive-
ness towards proliferative signals. Although the amounts of
SFRS18 did not show elevation in the non-involved epider-
mis, in vitro studies support the suggestion that the presence of
this protein could facilitate the effect of LUC7L3. All three
splicing regulators are notably elevated in psoriatic involved
epidermis, indicating that the mRNA maturation of fibro-
nectin is influenced by these proteins, and that these regulators
could also have multiple roles in disease development.
In future work, it would be interesting to clarify the
upstream regulatory elements maintaining the highly syn-
chronous expression of these three splicing factors and
whether these elements are altered in psoriasis. Moreover,
identification of additional mRNAs with altered expression
and/or splicing patterns under the regulation of the
LUC7L3, PPIG, and SFRS18 splicing factors might lead to
the identification of novel molecular patterns in psoriasis
pathogenesis.
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